Last Price
40.75
Today's Change
+0.49 (1.21%)
Day's Change
40.00 - 41.31
Trading Volume
22,663
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Ms. Renee Aguiar-Lucander Ms. Renee Aguiar-Lucander
Full Time Employees: 222 222
IPO Date: 2020-06-05 2020-06-05
CIK: 0001795579 0001795579
ISIN: US13124Q1067 US13124Q1067
CUSIP: 13124Q106 13124Q106
Beta: 1.46 1.46
Last Dividend: 0.00 0.00
Dcf Diff: 0.00 0.00
Dcf: 0.00 0.00
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.